Some DD information for the thoughtful investor...
One of the most exciting biotechnology companies in the market today is Mast Therapeutics (MSTX), a little known company developing an Orphan designated investigational agent (MST-188) that has potential to reduce ischemic tissue injury and end organ damage by restoring microvascular function. MSTX's current clinical focus is on two Orphan diseases: Sickle Cell Anemia ("SCD") and Acute Limb Ischemia ("ALI"). MSTX has already received Orphan Designation for SCD in the U.S and EU, and for ALI in the EU. The stock currently trades at 30 percent below its cash position, has no debt, and existing financial resources are more than adequate to fund the ongoing Phase 3 study in SCD, Phase 2 study in ALI, as well as additional studies for other indications. With a potential pharmaceutical treatment for multiple medical conditions affecting millions worldwide, MSTX is a significantly undervalued biotech with exponential upside.
Effective March, 2013, Adventrx Pharmaceuticals become known as Mast Pharmaceuticals, taking its name from the acronym (M)olecular (A)dhesion & (S)ealant (T)echnology Platform. In 2009, the majority of business operations were suspended and the workforce was reduced to only two employees. From 2009 to 2011 the company's primary focus was in oncology and the reformulation of drugs previously approved by the FDA. Like many small biotechs, the company's attempts to gain FDA approval for their oncology based drugs proved unsuccessful, and the company instead focused on clinical development of MST-188 for Sickle Cell Anemia (Phase 3) and Acute Limb Ischemia (Phase 2). MST-188 is the most clinically-advanced drug for SCD, and MSTX initiated a Phase 3 study in March 2013. MSTX expects to begin its Phase 2 study for ALI in late Q4 or early Q1 2014. They have received Orphan Designation for MST-188 for SCD in the U.S and EU and for ALI in the EU. Management intends to file for Orphan Designation for ALI in the U.S. later this year
Sentiment: Strong Buy